{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-046522","form_type":"8-K","ticker":null,"cik":"0001845337","company_name":"Day One Biopharmaceuticals, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.094885+00:00","generated_at":"2026-06-19T03:20:32.200396+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Day One Biopharmaceuticals amends bylaws for universal proxy rules and DGCL updates","bullets":["Bylaws revised to comply with SEC universal proxy rules (Rule 14a-19) and recent Delaware law changes.","Advance notice provisions updated: additional disclosures, nominee interview requirement, proxy card color rule.","Stockholders using universal proxy must certify compliance and provide evidence 5 business days before meeting.","Emergency bylaw provision added to allow Board quorum during crises.","Changes effective Feb 17, 2023; no impact on financials or operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-046522","json":"https://secwatch.observer/filing/0001193125-23-046522.json","markdown":"https://secwatch.observer/filing/0001193125-23-046522.md","text":"https://secwatch.observer/filing/0001193125-23-046522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/0001193125-23-046522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/d467705d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:20:32.200396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f71310a93143fbe0a63333b859b8c530707d4c2a","claim":"Day One Biopharmaceuticals, Inc.: Amended and restated bylaws to align with universal proxy rules, DGCL amendments, and other changes (effective 2023-02-17).","evidence_excerpt":"On February 17, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Day One Biopharmaceuticals, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845337/000119312523046522/0001193125-23-046522-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-17"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}